Statin-induced myopathy: a review and update

Bibliography

• Chatzizisis YS, Jonas M, Beigel R, Attenuation of inflammation and expansive remodeling by valsartan alone or in combination with simvastatin in high-risk coronary atherosclerotic plaques. Atherosclerosis 2009;203(2):387-94
   PubMed Web of Science ®Google Scholar
• Vaughan C, Gotto A Jr. Update on statins: 2003. Circulation 2004;110(7):886
   PubMed Web of Science ®Google Scholar
• Kotseva K, Wood D, De Backer G, EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009;16(2):121
   PubMed Web of Science ®Google Scholar
• Bruckert E, Hayem G, Dejager S, Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study. Cardiovasc Drugs Ther 2005;19(6):403-14
   PubMed Web of Science ®Google Scholar
• Ridker P, Danielson E, Fonseca F, ; JUPITER Trial Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein [published online ahead of print November 9, 2008]. N Engl J Med 2008;359(21):2195-207
   PubMed Web of Science ®Google Scholar
• Sung JC, Nichol MB, Venturini F, Factors affecting patient compliance with antihyperlipidemic medications in an HMO population. Am J Manag Care 1998;4(10):1421-30
   PubMed Web of Science ®Google Scholar
• Pasternak RC, Smith SC Jr, Bairey-Merz CN, ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 2002;106(8):1024
   PubMed Web of Science ®Google Scholar
• Sewright KA, Clarkson PM, Thompson PD. Statin myopathy: incidence, risk factors, and pathophysiology. Curr Atheroscler Rep 2007;9(5):389-96
   PubMedGoogle Scholar
• McKenney JM, Davidson MH, Jacobson TA, Guyton JR. Final conclusions and recommendations of the national lipid association statin safety assessment task force. Am J Cardiol 2006;97(8):S89-94
   Google Scholar
• Phillips P, Haas R. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2003;138(12):1008
   PubMed Web of Science ®Google Scholar
• Mohaupt MG, Karas RH, Babiychuk EB, Association between statin-associated myopathy and skeletal muscle damage. CMAJ 2009;181(1-2):E11
   PubMed Web of Science ®Google Scholar
• Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006;97(8A):52C
   PubMed Web of Science ®Google Scholar
• Silva MA, Swanson AC, Gandhi PJ, Tataronis GR. Statin-related adverse events: a meta-analysis. Clin Ther 2006;28(1):26-35
   PubMed Web of Science ®Google Scholar
• Kashani A, Phillips CO, Foody JAM, Risks associated with statin therapy. A systematic overview of randomized clinical trials. Circulation 2006;114(25):2788-97
   PubMed Web of Science ®Google Scholar
• Nichols G, Koro C. Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients. Clin Ther 2007;29(8):1761-70
   PubMed Web of Science ®Google Scholar
• Davidson M, Clark J, Glass L, Kanumalla A. Statin safety: an appraisal from the adverse event reporting system. Am J Cardiol 2006;97(8):S32-43
   Google Scholar
• Dirks A, Jones K. Statin-induced apoptosis and skeletal myopathy. Am J Physiol Cell Physiol 2006;291(6):C1208
   PubMed Web of Science ®Google Scholar
• McTaggart S. Isoprenylated proteins. Cell Mol Life Sci 2006;63(3):255-67
   PubMed Web of Science ®Google Scholar
• Vaklavas C, Chatzizisis YS, Ziakas A, Molecular basis of statin-associated myopathy. Atherosclerosis 2009;202(1):18
   PubMed Web of Science ®Google Scholar
• Harper CR, Jacobson TA. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr Opin Lipidol 2007;18(4):401
   PubMed Web of Science ®Google Scholar
• Guijarro C, Blanco-Colio L, Ortego M, 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 1998;83(5):490
   PubMed Web of Science ®Google Scholar
• Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 2007;49:2231-7
   PubMed Web of Science ®Google Scholar
• Chatzizisis YS, Vaklavas C, Giannoglou GD. Coenzyme Q10 depletion: etiopathogenic or predisposing factor in statin associated myopathy? Am J Cardiol 2008;101(7):1071
   PubMed Web of Science ®Google Scholar
• Caso G, Kelly P, McNurlan MA, Lawson WE. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 2007;99(10):1409-12
   PubMed Web of Science ®Google Scholar
• Young J, Florkowski C, Molyneux S, Effect of coenzyme Q10 supplementation on simvastatin-induced myalgia. Am J Cardiol 2007;100(9):1400-3
   PubMed Web of Science ®Google Scholar
• Laaksonen R, Jokelainen K, Sahi T, Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans*. Clin Pharmacol Ther 1995;57(1):62-6
   PubMed Web of Science ®Google Scholar
• Westwood F, Bigley A, Randall K, Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity. Toxicol Pathol 2005;33(2):246
   PubMed Web of Science ®Google Scholar
• Morita I, Sato I, Ma L, Murota S. Enhancement of membrane fluidity in cholesterol-poor endothelial cells pre-treated with simvastatin. Endothelium 1997;5(2):107-13
   PubMedGoogle Scholar
• Nishimoto T, Tozawa R, Amano Y, Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human myocytes. Biochem Pharmacol 2003;66(11):2133-9
   PubMed Web of Science ®Google Scholar
• Baker S. Molecular clues into the pathogenesis of statin-mediated muscle toxicity. Muscle Nerve 2005;31(5):572-80
   PubMed Web of Science ®Google Scholar
• Toth PP, Harper CR, Jacobson TA. Clinical characterization and molecular mechanisms of statin myopathy. Expert Rev Cardiovasc Ther 2008;6(7):955-69
   PubMedGoogle Scholar
• Mach F. Statins as immunomodulatory agents. Circulation 2004;109(21 Suppl 1):II15-17
   PubMedGoogle Scholar
• Kwak B, Mulhaupt F, Mach F. Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins. Autoimmun Rev 2003;2(6):332-38
   PubMed Web of Science ®Google Scholar
• Needham M, Fabian V, Knezevic W, Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul Disord 2007;17(2):194-200
   PubMed Web of Science ®Google Scholar
• Grable-Esposito P, Katzberg HD, Greenberg SA, Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 2010;41(2):185-90
   PubMed Web of Science ®Google Scholar
• Mammen A, Amato A. Statin myopathy: a review of recent progress. Curr Opin Rheumatol 2010;22(6):644
   PubMed Web of Science ®Google Scholar
• Rosenson RS. Current overview of statin-induced myopathy. Am J Med 2004;116(6):408-16
   PubMed Web of Science ®Google Scholar
• Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2007;82(6):726-33
   PubMed Web of Science ®Google Scholar
• Ghatak A, Faheem O, Thompson P. The genetics of statin-induced myopathy. Atherosclerosis 2010;219(2):337-43
   Google Scholar
• Niemi M. Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther 2009;87(1):130-3
   PubMed Web of Science ®Google Scholar
• Link E, Parish S, Armitage J, SLCO1B1 variants and statin-induced myopathy–a genomewide study. N Engl J Med 2008;359:789-99
   PubMed Web of Science ®Google Scholar
• Niemi M, Schaeffeler E, Lang T, High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenet Genomics 2004;14(7):429
   Google Scholar
• Voora D, Shah S, Spasojevic I, The SLCO1B1* 5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009;54(17):1609
   PubMed Web of Science ®Google Scholar
• Oh J, Ban MR, Miskie BA, Genetic determinants of statin intolerance. Lipids Health Dis 2007;6(1):7
   PubMedGoogle Scholar
• Vladutiu GD, Simmons Z, Isackson PJ, Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 2006;34(2):153-62
   PubMed Web of Science ®Google Scholar
• Armitage J. The safety of statins in clinical practice. Lancet 2007;370(9601):1781-90
   PubMed Web of Science ®Google Scholar
• Harper C, Jacobson T. Managing dyslipidemia in chronic kidney disease. J Am Coll Cardiol 2008;51(25):2375
   PubMed Web of Science ®Google Scholar
• Bar SL, Holmes DT, Frohlich J. Asymptomatic hypothyroidism and statin-induced myopathy. Can Fam Physician 2007;53(3):428
   PubMedGoogle Scholar
• Hsiang B, Zhu Y, Wang Z, A novel human hepatic organic anion transporting polypeptide (OATP2). J Biol Chem 1999;274(52):37161
   PubMed Web of Science ®Google Scholar
• Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289(13):1681
   PubMed Web of Science ®Google Scholar
• Huang S-M, Lesko L, Temple R. In: Waldman SA, Terzic A, editors, Adverse drug reactions and interactions in “Pharmacology and Therapeutics: Principles to Practice”. Chapter 20. Elsevier; 2009
   Google Scholar
• Davidson MH, Stein EA. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiology 1997;79(1):38-42
   PubMed Web of Science ®Google Scholar
• Brewer HB. Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams* 1. Am J Cardiol 2003;92(4):23-9
   Google Scholar
• Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med 2009;150(12):858
   PubMed Web of Science ®Google Scholar
• Silva M, Matthews ML, Jarvis C, Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther 2007;29(2):253-60
   PubMed Web of Science ®Google Scholar
• Ray GM. Antiretroviral and statin drug-drug interactions. Cardiol Rev 2009;17(1):44
   PubMed Web of Science ®Google Scholar
• Lee AJ, Maddix DS. Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. Ann Pharmacother 2001;35(1):26
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole*. Clin Pharmacol Ther 1998;63(3):332-41
   PubMed Web of Science ®Google Scholar
• Lewin JJ. Rhabdomyolysis with concurrent atorvastatin and diltiazem. Ann Pharmacother 2002;36(10):1546
   PubMed Web of Science ®Google Scholar
• Bottorff M. Statin safety and drug interactions: clinical implications. Am J Cardiol 2006;97(8):S27-31
   Google Scholar
• Becquemont L, Neuvonen M, Verstuyft C, Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics. Clin Pharmacol Ther 2007;81(5):679-84
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug administration. Information on simvastatin/amiodarone. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm095009.htm [Cited 2010]
   Google Scholar
• Chatzizisis Y, Koskinas K, Misirli G, Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf 2010;33(3):171-87
   PubMed Web of Science ®Google Scholar
• Schneck DW, Birmingham BK, Zalikowski JA, The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 2004;75(5):455-63
   PubMed Web of Science ®Google Scholar
• Jones P, Davidson M. Reporting rate of rhabdomyolysis with fenofibrate+ statin versus gemfibrozil+ any statin. Am J Cardiol 2005;95(1):120-2
   PubMed Web of Science ®Google Scholar
• Goosen TC, Bauman JN, Davis JA, Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid. Drug Metab Dispos 2007;35(8):1315
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Richards KM, Qiu Y, Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes. Pharm Res 2005;22(1):71-8
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Tang C, Qiu Y, Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 2002;30(11):1280
   PubMed Web of Science ®Google Scholar
• Jacobson TA. Myopathy with statin–fibrate combination therapy: clinical considerations. Nat Rev Endocrinol 2009;5:507-18
   PubMed Web of Science ®Google Scholar
• Nakagomi-Hagihara R, Nakai D, Tokui T. Inhibition of human organic anion transporter 3 mediated pravastatin transport by gemfibrozil and the metabolites in humans. Xenobiotica 2007;37(4):416-26
   PubMed Web of Science ®Google Scholar
• Reaven P, Witztum JL. Lovastatin, nicotinic acid, and rhabdomyolysis. Ann Intern Med 1988;109(7):597
   PubMed Web of Science ®Google Scholar
• Bays H. Safety of niacin and simvastatin combination therapy. Am J Cardiol 2008;101(8):S3-8
   PubMedGoogle Scholar
• Merk and Company. ZOCOR Prescribing information. New Jersey, USA: Whitehouse station May 2010
   Google Scholar
• Davidson MH, Maccubbin D, Stepanavage M, Striated muscle safety of ezetimibe/simvastatin (Vytorin). Am J Cardiol 2006;97(2):223-28
   PubMed Web of Science ®Google Scholar
• Conard SE, Bays HE, Leiter LA, Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease. Am J Cardiol 2008;102(11):1489-94
   PubMed Web of Science ®Google Scholar
• Leiter LA, Bays H, Conard S, Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. Am J Cardiol 2008;102(11):1495-501
   PubMed Web of Science ®Google Scholar
• Fux R, Morike K, Gundel UF, Ezetimibe and statin-associated myopathy. Ann Intern Med 2004;140(8):671
   PubMed Web of Science ®Google Scholar
• Simard C, Pharm B, Poirier P. Ezetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Can J Cardiol 2006;22(2):141
   PubMed Web of Science ®Google Scholar
• Stein EA, Ballantyne CM, Windler E, Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins. Am J Cardiol 2008;101(4):490-6
   PubMed Web of Science ®Google Scholar
• Thompson PD, Clarkson PM, Rosenson RS. An assessment of statin safety by muscle experts. Am J Cardiol 2006;97(8A):69C-76C
   PubMed Web of Science ®Google Scholar
• Chatzizisis YS, Koskinas KC, Misirli G, Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf 2010;33(3):171-87
   PubMed Web of Science ®Google Scholar
• Jacobson T. Toward “pain-free” statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc 2008;83(6):687-700
   PubMed Web of Science ®Google Scholar
• Ahmed W, Khan N, Glueck CJ, Low serum 25 (OH) vitamin D levels (< 32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients. Transl Res 2009;153(1):11-16
   PubMed Web of Science ®Google Scholar
• Eckel RH. Approach to the patient who is intolerant of statin therapy. J Clin Endocrinol Metab 2010;95(5):2015
   PubMed Web of Science ®Google Scholar
• Harper C, Jacobson T. Evidence-based management of statin myopathy. Curr Atheroscler Rep 2010;12(5):322-30
   PubMed Web of Science ®Google Scholar
• Gazi IF, Daskalopoulou SS, Nair DR, Mikhailidis DP. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr Med Res Opin 2007;23(9):2183-92
   PubMed Web of Science ®Google Scholar
• Staffa J, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002;346(7):539
   PubMed Web of Science ®Google Scholar
• Ruisinger JF, Backes JM, Gibson CA, Moriarty PM. Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance. Am J Cardiol 2009;103(3):393-94
   PubMed Web of Science ®Google Scholar
• Backes JM, Moriarty PM, Ruisinger JF, Gibson CA. Effects of once weekly rosuvastatin among patients with a prior statin intolerance+. Am J Cardiol 2007;100(3):554-55
   PubMed Web of Science ®Google Scholar
• Gadarla M, Kearns AK, Thompson PD. Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins. Am J Cardiol 2008;101(12):1747-8
   PubMed Web of Science ®Google Scholar
• Glueck CJ, Aregawi D, Agloria M, Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies. Clin Ther 2006;28(6):933-42
   PubMed Web of Science ®Google Scholar
• Backes JM, Venero CV, Gibson CA, Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance (March). Ann Pharmacother 2008;42(3):341-6
   PubMed Web of Science ®Google Scholar
• Mackie BD, Satija S, Nell C, Monday, Wednesday, and Friday dosing of rosuvastatin in patients previously intolerant to statin therapy. Am J Cardiol 2007;99(2):291
   PubMed Web of Science ®Google Scholar
• Athyros VG, Tziomalos K, Kakafika AI, Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients. Am J Cardiol 2008;101(4):483-5
   PubMed Web of Science ®Google Scholar
• Degreef LE, Opdam FL, Teepe-Twiss IM, The tolerability and efficacy of low-dose simvastatin in statin-intolerant patients. Eur J Intern Med 2010;21(4):293-6
   PubMed Web of Science ®Google Scholar
• Lu Z, Kou W, Du B, Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol 2008;101(12):1689
   PubMed Web of Science ®Google Scholar
• Becker DJ, Gordon RY, Halbert SC, Red yeast rice for dyslipidemia in statin-intolerant patients. Ann Intern Med 2009;150:830-9
   PubMed Web of Science ®Google Scholar
• Halbert SC, French B, Gordon RY, Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol 2010;105(2):198-204
   PubMed Web of Science ®Google Scholar
• Rivers S, Kane M, Busch R, Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance. Endocr Pract 2007;13(1):11-16
   PubMedGoogle Scholar